Skip to main content
News Icon

COVIMMUNE being funded

A new consortium COVIMMUNE under the direction of Prof. Eicke Latz, speaker of the cluster of Excellence ImmunoSensation2 is being funded with around 2 Million Euros by the Federal Ministry of Education and Research (BMBF). The project "Understanding divergent host reactions to SARS-CoV-2 infections by precision immunology" (COVIMMUNE) brings together clinical researchers at the University Hospital Bonn who are involved in COVID-19 patient care with basic scientists with immunological expertise from the University of Bonn.

"We want to find out the connection between the mechanisms of the immune response to the SARS-CoV-2 infection and the clinical course of the disease," says Prof. Dr. Eicke Latz. Around two dozen personalities from disciplines such as virology, internal medicine, intensive care medicine, pulmonology, neurology, immunology, blood coagulation, bioinformatics and systems biology are involved. Together they want to contribute to a better understanding of the different course of the disease in SARS-CoV-2 infections. Prof. Natalio Garbi heads the sub-project of the consortium on adaptive immunity. He says: "We want to test whether the interaction of the innate and the acquired (adaptive) immune response is the key to eliminating the infection and developing long-term immunity without long-term health consequences."

The aim is to find out how the SARS-CoV-2 virus can trigger a misdirected immune response and what role this plays in severe COVID-19 disease courses. Furthermore, a clinical study will investigate which factors cause long-term damage to the lungs and the nervous system. Prof. Dr. Michael Heneka, whose sub-project in the consortium is looking at the secondary diseases of the lungs and the central nervous system caused by COVID-19, says: "It is not yet well understood how infection with the SARS-CoV-2 virus can trigger such secondary diseases. We want to examine these relationships in a clinical study in order to be able to offer better treatment options."


Contact

Prof. Dr. Eicke Latz

Institute of Innate Immunity, University of Bonn

Phone: 0228/287-51223

E-Mail: eicke.latz@uni-bonn.de

Related news

Gruppenbild Preistrager Lisec Artz Preisverleihung

News categories: Honors & Funding

Niklas Klümper and Varun Venkataramani receive Lisec-Artz Prize

Privatdozent Niklas Klümper of the University Hospital Bonn and Dr. Varun Venkataramani of the Faculty of Medicine at Heidelberg University and have been awarded the Lisec Artz Prize for their outstanding cancer research. The University of Bonn Foundation and the University of Bonn Faculty of Medicine presented the awards to the two researchers on Tuesday, November 18, 2025 at the University Hospital Bonn (UKB) as part of the Cluster Science Days event held by the ImmunoSensation² Cluster of Excellence. The prize is worth a total of 15,000 euros.
View entry
20251103 PM Prof Wihelm

News categories: Honors & Funding

Prof. Christoph Wilhelm receives €1.25 million DFG funding for Reinhart-Koselleck project

The German Research Foundation (DFG) is funding a Reinhart-Koselleck project at the University Hospital Bonn (UKB) within the Cluster of Excellence ImmunoSensation² at the University of Bonn with €1.25 million. The research team led by Prof. Christoph Wilhelm, Chair of Immunopathology at the Institute of Clinical Chemistry and Clinical Pharmacology, aims to investigate how the body maintains the balance of the gut microbiome during periods of illness and food scarcity.
View entry
Kato research group

News categories: Publication

Ominous false alarm in the kidney

Bonn researchers have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering a chain reaction. In cooperation with Nanyang Technological University Singapore and the University Hospital Würzburg, among others, the study provides an explanation for how a point mutation in the immune receptor RIG-I transforms the body's defense system into a self-destructive force and causes severe organ-specific autoimmune diseases. The results have now been published in the journal Science Immunology.
View entry

Back to the news overview